BR112017018522A2 - composições e métodos para diagnóstico e tratamento do câncer - Google Patents
composições e métodos para diagnóstico e tratamento do câncerInfo
- Publication number
- BR112017018522A2 BR112017018522A2 BR112017018522A BR112017018522A BR112017018522A2 BR 112017018522 A2 BR112017018522 A2 BR 112017018522A2 BR 112017018522 A BR112017018522 A BR 112017018522A BR 112017018522 A BR112017018522 A BR 112017018522A BR 112017018522 A2 BR112017018522 A2 BR 112017018522A2
- Authority
- BR
- Brazil
- Prior art keywords
- treatment
- compositions
- methods
- cancer diagnosis
- relates
- Prior art date
Links
- 238000003745 diagnosis Methods 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 102100023832 Prolyl endopeptidase FAP Human genes 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 108010072257 fibroblast activation protein alpha Proteins 0.000 abstract 2
- 230000004913 activation Effects 0.000 abstract 1
- 210000002950 fibroblast Anatomy 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21026—Prolyl oligopeptidase (3.4.21.26), i.e. proline-specific endopeptidase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/81—Protease inhibitors
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Urology & Nephrology (AREA)
- Public Health (AREA)
- Physics & Mathematics (AREA)
- Animal Behavior & Ethology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Pharmacology & Pharmacy (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
a presente invenção se refere ao diagnóstico e ao tratamento de doenças cancerosas, em particular, doenças cancerosas que expressam seprase (fap-alfa, proteína alfa de ativação de fibroblastos). mais particularmente, a invenção se refere-se a peptídeos visando seprase.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2015/055560 WO2016146174A1 (en) | 2015-03-17 | 2015-03-17 | Compositions and methods for diagnosis and treatment of cancer |
| PCT/EP2016/055601 WO2016146639A1 (en) | 2015-03-17 | 2016-03-15 | Compositions and methods for diagnosis and treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112017018522A2 true BR112017018522A2 (pt) | 2018-04-17 |
Family
ID=52684233
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112017018522A BR112017018522A2 (pt) | 2015-03-17 | 2016-03-15 | composições e métodos para diagnóstico e tratamento do câncer |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US10370433B2 (pt) |
| EP (1) | EP3271385B1 (pt) |
| JP (1) | JP6739132B2 (pt) |
| KR (1) | KR102414718B1 (pt) |
| CN (1) | CN107531776B (pt) |
| AU (1) | AU2016232301B2 (pt) |
| BR (1) | BR112017018522A2 (pt) |
| CA (1) | CA2979768C (pt) |
| ES (1) | ES2747727T3 (pt) |
| HK (1) | HK1247931A1 (pt) |
| MX (1) | MX2017011794A (pt) |
| WO (2) | WO2016146174A1 (pt) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110291401B (zh) | 2016-12-14 | 2023-04-11 | 普渡研究基金会 | 成纤维细胞活化蛋白(fap)-靶向成像和治疗 |
| WO2019233605A1 (en) * | 2018-06-08 | 2019-12-12 | BioNTech SE | Compositions and methods for diagnosis and treatment of cancer |
| GB201820320D0 (en) * | 2018-12-13 | 2019-01-30 | Bicyclerd Ltd | Bicyclic peptide ligands specific for FAPalpha |
| KR20220044732A (ko) | 2019-07-03 | 2022-04-11 | 페프티드림 아이엔씨. | Cd38-결합제 및 이의 용도 |
| EP3763726A1 (en) | 2019-07-08 | 2021-01-13 | 3B Pharmaceuticals GmbH | Compounds comprising a fibroblast activation protein ligand and use thereof |
| AU2020309161A1 (en) | 2019-07-08 | 2022-01-27 | 3B Pharmaceuticals Gmbh | Compounds comprising a fibroblast activation protein ligand and use thereof |
| MX2022000252A (es) * | 2019-07-08 | 2022-02-21 | 3B Pharmaceuticals Gmbh | Compuestos que comprenden un ligando de proteina de activacion de fibroblasto y uso del mismo. |
| CN112409414B (zh) * | 2020-12-01 | 2021-10-26 | 北京师范大学 | 锝-99m标记含异腈的FAPI衍生物及制备方法和应用 |
| KR20230129261A (ko) | 2021-01-07 | 2023-09-07 | 쓰리비 파마슈티컬스 게엠베하 | 섬유모세포 활성화 단백질 리간드를 포함하는 화합물및 그의 용도 |
| EP4050018A1 (en) | 2021-01-07 | 2022-08-31 | 3B Pharmaceuticals GmbH | Compounds comprising a fibroblast activation protein ligand and use thereof |
| WO2023094704A1 (en) * | 2021-11-29 | 2023-06-01 | Navigo Proteins Gmbh | Specific binding molecules for fibroblast activation protein (fap) |
| WO2024165072A1 (zh) * | 2023-02-10 | 2024-08-15 | 成都纽瑞特医疗科技股份有限公司 | 一种多肽化合物及其应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE278958T1 (de) * | 1996-03-20 | 2004-10-15 | Dyax Corp | Reinigung des gewebe plasminogenaktivators (tpa) |
| US6884770B1 (en) * | 1998-11-06 | 2005-04-26 | Curis, Inc. | Methods and compositions for treating or preventing peripheral neuropathies |
| US6951839B1 (en) * | 1999-11-30 | 2005-10-04 | Curis, Inc. | Methods and compositions for regulating lymphocyte activity |
| AU2005287557B2 (en) * | 2004-09-21 | 2011-10-13 | Biontech Ag | Use of microproteins as tryptase inhibitors |
| US7374898B2 (en) * | 2004-10-12 | 2008-05-20 | The Research Foundation Of State University Of New York | Peptide inhibitors against seprase |
| ES2417153T5 (es) * | 2006-03-06 | 2024-04-04 | Amunix Operating Inc | Polímeros recombinantes no estructurados y usos de los mismos |
| JP5563988B2 (ja) * | 2007-12-10 | 2014-07-30 | エフ．ホフマン−ラ ロシュ アーゲー | 癌のマーカーとしてのセプラーゼ |
| WO2012027159A1 (en) * | 2010-08-23 | 2012-03-01 | NanoRx, Inc. | Policosanol nanoparticles |
| CN102643847A (zh) * | 2011-02-17 | 2012-08-22 | 华东理工大学 | 多基因共表达体系及含二硫键功能性蛋白的生产方法 |
| EP2831275A1 (de) * | 2012-03-27 | 2015-02-04 | Protagen AG | Markersequenzen für rheumatoide arthritis |
| GB201218278D0 (en) * | 2012-10-11 | 2012-11-28 | Cyclogenix Ltd | Translocating peptide |
-
2015
- 2015-03-17 WO PCT/EP2015/055560 patent/WO2016146174A1/en active Application Filing
-
2016
- 2016-03-15 ES ES16712761T patent/ES2747727T3/es active Active
- 2016-03-15 US US15/552,215 patent/US10370433B2/en active Active
- 2016-03-15 AU AU2016232301A patent/AU2016232301B2/en active Active
- 2016-03-15 CN CN201680015916.1A patent/CN107531776B/zh active Active
- 2016-03-15 KR KR1020177026055A patent/KR102414718B1/ko active IP Right Grant
- 2016-03-15 BR BR112017018522A patent/BR112017018522A2/pt active Search and Examination
- 2016-03-15 CA CA2979768A patent/CA2979768C/en active Active
- 2016-03-15 WO PCT/EP2016/055601 patent/WO2016146639A1/en active Application Filing
- 2016-03-15 EP EP16712761.2A patent/EP3271385B1/en active Active
- 2016-03-15 JP JP2017549007A patent/JP6739132B2/ja active Active
- 2016-03-15 MX MX2017011794A patent/MX2017011794A/es active IP Right Grant
-
2018
- 2018-06-01 HK HK18107216.3A patent/HK1247931A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN107531776B (zh) | 2022-01-25 |
| EP3271385B1 (en) | 2019-07-03 |
| CA2979768A1 (en) | 2016-09-22 |
| ES2747727T3 (es) | 2020-03-11 |
| AU2016232301B2 (en) | 2020-12-24 |
| US10370433B2 (en) | 2019-08-06 |
| KR20170121215A (ko) | 2017-11-01 |
| NZ734680A (en) | 2022-03-25 |
| JP6739132B2 (ja) | 2020-08-12 |
| CN107531776A (zh) | 2018-01-02 |
| MX2017011794A (es) | 2018-02-19 |
| JP2018515066A (ja) | 2018-06-14 |
| AU2016232301A1 (en) | 2017-09-07 |
| WO2016146174A1 (en) | 2016-09-22 |
| HK1247931A1 (zh) | 2018-10-05 |
| CA2979768C (en) | 2022-07-05 |
| KR102414718B1 (ko) | 2022-06-30 |
| WO2016146639A1 (en) | 2016-09-22 |
| EP3271385A1 (en) | 2018-01-24 |
| US20180037632A1 (en) | 2018-02-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112017018522A2 (pt) | composições e métodos para diagnóstico e tratamento do câncer | |
| JOP20200192A1 (ar) | أجسام مضادة لـ tigit | |
| MX2023014569A (es) | Anticuerpos anti-sirpa. | |
| MX2022007522A (es) | Anticuerpos anti-cd27. | |
| BR112018007453A2 (pt) | genes modificados de ataxia de friedreich e vetores para a terapia gênica | |
| TW201613901A (en) | New compounds | |
| CR20120508A (es) | PROTEÍNA DE FUSIÓN ROBO1-Fc Y SU UTILIZACIÓN EN EL TRATAMIENTO DE TUMORES | |
| CL2015003343A1 (es) | Composición farmacéutica que comprende un agente terapéutico modificado en base a hemoglobina, para el tratamiento para tratar el cáncer, e imágenes de diagnóstico. | |
| CL2015002571A1 (es) | Composiciones y métodos para le diagnostico y tratamiento del cáncer hepático. | |
| BR112017005202A2 (pt) | anticorpos anti-met e composições | |
| MX2015014046A (es) | Combinaciones de farmacos para tratar cancer. | |
| BR112018003178A2 (pt) | absorvente feminino com braçadeiras de barreira | |
| ECSP15011764A (es) | Antiandrógenos para el tratamiento del cáncer de próstata resistente a la castración no metastásico | |
| MX2016012835A (es) | Composiciones y metodos para tratar las espinillas. | |
| BR112018003526A2 (pt) | métodos de tratamento de doenças inflamatórias | |
| TR201910866T4 (tr) | Kanser tedavisi için birleşik preparasyonlar. | |
| CO2017001087A2 (es) | Anticuerpos anti proteína similar a angiopoyetina 4 | |
| BR112017014189A2 (pt) | terapia de câncer com um parvovirus combinado com bevacizumabe | |
| MX2020000636A (es) | Proteinas sinteticas y usos terapeuticos de las mismas. | |
| IN2013MU03118A (pt) | ||
| PH12017501979A1 (en) | Pharmaceutical compound | |
| IN2013MU02576A (pt) | ||
| BR112016007816A2 (pt) | composições peptídicas inovadoras | |
| MA40363A (fr) | Agents de liaison de rspo1 et leurs utilisations |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] |